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Mycophenolate mofetil limits renal damage and prolongs life in murine
lupus autoimmune disease. Classical immunosuppressants like cyclophos-
phamide give excellent results in human lupus nephritis. However, they
augment malignancies and viral infections. Here we investigated the effect
of the new immunosuppressant agent, mycophenolate mofetil (MMF), in
New Zealand Black x New Zealand White (NZBxW) Fl hybrid mice, a
model of genetically determined immune complex disease that mimics
systemic lupus in humans. MMF has a selective antiproliferative effect on
T- and B-lymphocytes, inhibits antibody formation and blocks the glyco-
sylation of lymphocyte glycoproteins involved in the adhesion of leuko-
cytes to endothelial cells. Two groups of NZBxW mice were used: group
1 (N = 20) given daily MMF (60 mg/kg p.o.) and group 2 (N = 15) given
daily vehicle alone. Treatment started at three months of age and lasted
until the death of the animals. Results showed that percentage of
proteinuric mice was significantly reduced by MMF treatment and serum
BUN levels were also lower than vehicle. MMF had a suppressive effect on
autoantibody production and protected animals from leukopenia and
anemia. Life survival of MMF treated lupus mice was significantly
improved in respect to untreated animals. Thus, MMF delayed renal
function deterioration and prolonged life survival in murine lupus nephri-
tis. MMF has been already recognized as reasonably well tolerated in renal
transplant patients and despite its gastrointestinal toxicity its overall safety
profile appears superior to azathioprine. Human studies are needed to
establish whether MMF may function as a steroid-sparing drug in lupus
nephritis.
Female New Zealand Black x New Zealand White (NZBxW)
Ft mice are known to develop an autoimmune disease reminis-
cent to human systemic lupus erythematosus (SLE) [1, 21. The
disease manifests at the age of 6 to 7 months with polyclonal
B-cell activation, excessive synthesis of anti-nuclear antibodies
and other autoantibodies that by reacting to nuclear and endog-
enous antigens form immune complexes [1—3]. Those are easily
detected in the circulation but additionally form and deposit in
situ in various organs including the kidney. At glomerular level
deposited immune complexes initiate an inflammatory reaction
severe enough to produce renal failure and death [3]. New
concepts have emerged in recent years that have highlighted a
dysregulation of apoptosis in SLE as a crucial condition for
presentation and recognition of autoantigens and for production
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of autoantibodies [4, 5]. Specifically, it has been proposed that
nucleosomes (that is, DNA complexed to histones) are released
from aberrant apoptic cells (decreased phagocytosis might be a
contributing factor) and are presented to, and recognized by
auto-reactive T-cells [4]. Persisting nucleosome-specific T-cells
would provide help for production of anti-nucleosome and anti-
DNA antibodies. Then positively charged histones within the
nucleosomal part of the immune complex could interact with
anionic structures in the GBM, such as heparan sulfate, and
mediate the glomerular deposition of autoantibodies [3—8]. This
interaction might lead to albuminuria by neutralization of charge
or by eliciting an inflammatory reaction [9]. At the same time
nucleosomes might bind to various sites within the glomerulus and
serve as planted antigens for subsequent interactions with auto-
antibodies to form immune complexes in situ [3, 4]. In this respect
both histones and DNA have been identified in glomerular
immune deposits either in human [7] or murine [10] lupus
nephritis, and in one study the deposition of histones was almost
exclusively found in albuminuric mice [10], thus underlining the
role of histones and nucleosomes in the development of albumin-
uria.
The above murine model was extensively employed in the past
to test new molecules of potential interest for the therapy of
human lupus. Data are available that cyclophosphamide and
methyiprednisolone with or without azathioprine can effectively
delay the progression of the renal disease of lupus mice [11—131.
However, the use of the above drugs in humans is known for its
major side effect, the most severe of which remain infections and
cancer [14]. This has justified extensive pre-clinical research
addressed to find less toxic alternatives. Mycophenolate mofetil
(MMF), RS-61443, is a new immunosuppressant agent [15, 16]
that contains as its active component mycophenolic acid, a
well-characterized inhibitor of eukariotic inosine 5' -monophos-
phate dehydrogenase (IMPD), the rate controlling enzyme in de
novo biosynthesis of guanosine triphosphate (GTP). It selectively
decreases intracellular guanine nucleotide pools and specifically
suppresses purine de novo biosynthesis. Since antigen-activated B-
and T-cells are highly dependent on de novo synthesis of purines,
whereas most other cells can utilize a salvage pathway, MMF has
a selective antiproliferative activity on lymphocytes [17] that is
reversible. In vitro MMF, besides blocking the proliferation of
B-cells, inhibits antibody formation and the generation of cyto-
toxic T-cells [171. By depleting GTP, which is required for the
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transfer of sugar moieties onto glycoprotein precursor molecules
[15], MMF also down-regulates the expression of those lympho-
cyte glycoproteins which crucially sustain cell adhesion.
Human trials have documented that MMF alone or in combi-
nation with other immunosuppressants effectively prevents acute
or recurrent rejection of solid organs [16, 18—22] better than
azathioprine. Thus, two randomized trials of MMF combined with
cyclosporine and corticosteroids given for prevention of acute
rejection in cadaveric renal allograft—that collectively involved a
total of 1,000 patients—found that MMF significantly reduced the
rate of biopsy-proven rejection during the first six months after
transplantation and was well tolerated [21, 22]. These data of less
hematological toxicity as compared to azathioprine, without sig-
nificant renal and liver toxicities and no significant incidence of
infections have pushed MMF already in clinical practice to
become an excellent alternative to the older antimetabolites.
Finally, studies in patients with an autoimmune disease like
rheumatoid arthritis indicated that oral administration of MMF
was well tolerated, with no nephrotoxicity, hepatotoxicity, myelo-
suppression or other limiting side effects [23].
Here we report the results of the first study in lupus prone
NZBxW mice on the therapeutic properties of MMF, intended as
pre-clinical step to explore the possibilities that MMF may have a
future role in the treatment of the corresponding human disease.
Methods
Experimental design
NZBxW Fl female mice (Charles River Italia s.p.a., Calco,
Italy), two months of age at the start of the experiment, were used
in these studies. Animal care and treatment were conducted in
conformity with the institutional guidelines that are in compliance
with national and international laws and policies (EEC Council
Directive 86/609, OJL 358, Dec 1987; NIH Guide for the Care and
Use of Laboratory Animals, NIH Publication No. 85-23, 1985). All
animals were housed in a constant temperature room with a
12-hour dark 12-hour light cycle and fed a standard diet. Animals
were divided into two groups. Group I (N = 20) was orally given
the immunosuppressive agent MMF (RS-61443; Syntex Develop-
ment Research, Palo Alto, CA, USA) as a daily administration at
the dose of 60 mg/kg [17]. Group 2 (N = 15) was orally given the
drug vehicle (0.5% carboxy-methylcellulose; Sigma Chemical Co,
St. Louis, MO, USA). Treatment started at three months of age
and lasted until mice died or were terminally ill. At three months
of age, before the onset of renal disease [1, 2] and before starting
treatment, all mice were housed in metabolic cages and 24 hour
urines were collected for determination of basal urinary protein
excretion levels. Baseline values of urinary protein excretion
ranged from 0.33 to 2.92 mg/day. Thus, levels exceeding 3 mg/day
during the subsequent follow-up were considered abnormal. Uri-
nary protein excretion was then measured every two weeks, Blood
was collected from the ophthalmic venous plexus for hematocrit,
white blood cell and platelet counts and serum BUN level
measurements at 3 (basal), 6, 8, 10 and 12 months of age. Serum
anti-DNA antibodies were measured before treatment (3 months
of age) for baseline values and then at 8 months of age. Body
weight was evaluated at 3 (basal), 6, 8, 10 and 12 months of age in
all mice. At the end of the study renal tissue specimens were
removed for histological analysis by light microscopy.
Two additional groups of NZBxW mice were used to evaluate
the therapeutic effect of MMF on animal survival. Group 3 (N =
19) was orally given MMF (60 mg/kg/day) and group 4 (N = 15)
was orally given the drug vehicle. Treatment started at five months
of age when approximately 10% of NZBxW mice have proteinuria
levels exceeding 3 mg/day.
Proteinuria and renal fsnction
Urinary protein concentration was determined by the Coomas-
sie blue G dye-binding assay with BSA as standard [24]. Renal
function was assessed as BUN on serum samples using an
enzymatic UV Rate by Sincron CX-5 (Beckman Instruments,
Fullerton, CA, USA).
Anti-DNA antibodies
The levels of anti-dsDNA autoantibodies were evaluated by an
enzyme-immunoassay (Diastat anti-ds DNA kit; Bouty Labora-
tory, Milano, Italy). The assay was carried out according to the
manifacturer's instructions with a modification due to the replace-
ment of the alkaline phosphatase (AP) conjugated goat anti-
human immunoglobulin (Ig) G+M antibody with a AP-conju-
gated goat anti-mouse IgG+M antibody. Each serum sample,
diluted 1:200 in assay diluent buffer, was plated in antigen (calf
thymus DNA)-coated 96-well microplates; in addition, three
different concentrations of the standard antibody were plated.
Plates were then incubated for 30 minutes at 37°C and subse-
quently washed four times with 250 rl of washing buffer. Then,
100 1.d of a 1:500 dilution in assay diluent buffer of AP-conjugated
goat anti mouse IgG+M antibodies (Sigma Chemical Co.) were
added to the wells containing the mouse serum samples, whereas
100 d of a 1:100 dilution of AP-conjugated anti-human IgG+M
antibodies were added to the wells in wich the standard had been
plated. Control wells were prepared both for the anti-human Ig
and for the anti-mouse Ig antibodies in order to verity different
background levels. Plates were then incubated and washed as
above. Finally, 100 pJ of substrate buffer, in which substrate
tablets had been dissolved (1 tablet/5 ml of substrate buffer), were
then added to each well. After incubation for 45 minutes at 37°C,
plates were read at 405 nm in a Titertek Multiskan Plus apparatus
(Flow Labs., Milano, Italy).
A standard curve was established for each plate and used to
calculate the units/mi (U/mI) present in each specimen. As the
standards provided in the kit were referred to human autoanti-
bodies whereas in the present work murine antibodies were
measured, the results were thereafter expressed in "Equivalents"
of U/mI of autoantibodies.
Hematological parameters
Leukocytes and platelets were counted by phase-contrast mi-
croscopy. Hematocrit values were determined by routine labora-
tory methods.
Renal morphology
Light microscopy. Fragments of renal cortex were fixed in
Dubosq-Brazii, dehydrated in alcohol and embedded in paraffin.
Sections (3 jsm) were stained with hematoxylin and eosin, Mas-
son's trichrome, periodic acid-Schift's reagent (PAS-stain). Each
biopsy included at least 100 glomeruli. Glomerular intracapillary
hypercellularity was quantitated by a scoring system from 0 to 3 +
(0 = no hyperceilularity; 1 + = mild; 2+ = moderate; and 3+ =
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severe). Extracapillaiy proliferation was graded from 0 to 3 + (0 =
no hypercellularity; 1 + = less than 25% of glomeruli involved; 2+
= 25% to 50% of glomeruli involved; 3+ = more than 50% of
glomeruli involved). Glomerular deposits were graded from 0 to
3+ (0 = no deposits; I + = less than 25% of glomeruli involved;
2+ 25% to 50% of glomeruli involved; 3+ = more than 50% of
glomeruli involved). Tubular (atrophy, casts and dilation) and
interstitial changes (fibrosis and inflammation) were graded from
0 to 3+ (0 = no changes; 1+ = changes affecting less than 25%
of the sample; 2+ = changes affecting 25 to 50% of the sample;3+ = changes affecting more than 50% of the sample). All renal
biopsies have been analyzed by the same pathologist, in a single-
blind fashion.
Statistical analysis
Data are expressed as mean SE. Results were analyzed by
Student's t-test for paired or unpaired data (hematological param-
eters), log-rank test (BUN, proteinuria, survival) or one-way
analysis of variance with Tukey test for multiple comparisons
(anti-DNA antibodies, body wts) as appropriate [25]. Estimates of
renal damage by morphological studies were compared with
Mann-Whitney U-test. Statistical significance was defined as P <
0.05.
Results
Effect of MMF on proteinuria
Cumulative percentage of mice with heavy proteinuria (that is,
> 3 mg/day) in vehicle and MMF-treated groups is shown in
Figure 1. In vehicle group the percentage of mice with proteinuria
progressively increased during time, reaching 60% and 100% at 8
and 15 months of age, respectively. Treatment with MMF delayed
the onset of heavy proteinuria in comparison to the vehicle.
Therefore, at 8, 10 and 12 months of age the percentage of
MMF-treated mice with heavy proteinuria was significantly lower
than that of mice given vehicle (8 months, 20% vs. 60%, 10
Months
ofage
% Mice BUN > 30 mg/dl (BUN range, mg/dl)
3 8 10 12
Vehicle
MMF
0%
0%
55%
(31—322 mgldl)
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(32—78 mg/dl)
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(33—276 mg/dl)
33%
(31—73 mg/dl)
100%
(36—94 mg/dl)
33%
(39—93 mg/dl)
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Fig. 2. Senim levels of anti-DNA antibodies at three months of age (before
treatment, basal), and at eight months of age in NZBxW mice given vehicle
or MMF. Data are expressed as mean SE. *p < 0.01 versus basal, °P <
0.01 versus vehicle.
months, 35% vs. 80%, 12 months, 65% vs. 93%, 15 months, 70%
vs. 100%, P < 0.005).
Effect of MMF on renal function
Basal levels of BUN as determined in all mice at three months
of age ranged from 14 to 29 mg/dl. Thus values exceeding 30 mg/dl
were considered abnormal. Table 1 shows the percentage of
vehicle or MMF-treated lupus mice with BUN levels > 30 mg/dl
throughout the experimental period. In vehicle group renal
function progressively deteriorated with time so that at 8, 10 and
12 months of age 55%, 67% and 100% of animals, respectively,
had BUN> 30 mg/dl. MMF treatment effectively limited deteri-
oration of renal function. Thus, only 16% and 33% of MMF-
treated mice had impaired renal function at 8 and 12 months of
age, respectively. Actually, over time BUN values of MMF-
treated mice were significantly lower than those of mice given
vehicle (basal, 23 0.7 vs. 23 0.8 mg/dl; month 8, 29 3 vs.
144 37 mg/dl, P < 0.03; month 10, 34 4 vs. 84 48 mg/dl, P <
0.02; month 12, 34 6 vs. 61 17 mg/dl, P < 0.01).
Effect of MMF on anti-DNA antibody
Serum levels of circulating anti-DNA antibodies were measured
at three months of age before treatment and at eight months of
age in vehicle and MMF-treated mice (Fig. 2). Before treatment
animals in both groups had similar levels of anti-DNA antibodies
ranging from 15.8 to 18.9 U/mI. Untreated lupus mice at eight
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Table 1. Percentage of NZBxW lupus mice with BUN > 30 mg/dl
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Fig. 1. Cumulative percentage of proteinuria (>3 mg/day) in NZBxW mice
given vehicle (E) or MMF () at different months of age. Each point reflects
the Current level of proteinuria in surviving mice as well as the last
measurement in deceased mice. *p < 0.005 versus vehicle.
The reported range of BUN levels for mice with impaired renal function
(BUN > 30 mg/dl) is in parenthesis.
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Table 2. Hematological parameters in NZBxW lupus mice given vehicle or MMF
Months of age
3 6 8 10 12
Platelet count Vehicle 107.2 5.4 97.2 5.5 95.2 8.5
i04/p.l MMF 101.2 4.4 94.8 3.2 101.9 4.4
White blood cell count Vehicle 4.0 0.1 3.6 0.4 3.5 0.4
103/pl MMF 3.9 0.1 3.6 0.3 3.8 0.2
Hematocrit % Vehicle 48.1 0.8 46.0 0.5 40.1 1.5a
MMF 48.2 0.9 48.6 0.4 45.6 1.0
72.6 8.5a
86.8 5.4
2.9 0.4k'
3.7 0.4
29.8 13b
38.8 2.4'
61.0 11.oa
78.2 6.9
2.6 o.sa
3.8 Ole
29.3 4.2a
39.2 0.5k"
All results are expressed as mean SE.
a P < 0.05, P < 0.01 vs. month 3
P < 0.02, d P < 0.01 vs. vehicle at corresponding time
Table 3. Body weight in NZBxW lupus mice given vehicle or MMF
Months of age
3 6 8 10 12
Body weight g
Vehicle 29.13 0.51 33.46 0.87 32.50 1.00
MMF 31.05 0.30 33.50 0.44 34.94 0.67
34.16 0.97
36.18 0.83
31.00 1.68
35.23 0.95
All results are expressed as mean SE.
months of age exhibited increased levels of anti-DNA antibodies
(51.3 9.9 U/ml, P < 0.01 vs. month 3). By contrast, MMF
treatment reduced to a significant extent the production of
anti-DNA antibodies (24.5 1.9 U/mi, P < 0.01 vs. vehicle).
Effect of MMF on hematological parameters
Platelet and white blood cell count and hematocrit were
evaluated in lupus mice given vehicle or MMF at different time
intervals. As shown in Table 2 a significant decrease in all
parameters was observed in vehicle group starting from 10 months
of age. As compared to vehicle MMF treatment significantly
protected animals from leukopenia and anemia. If anything, in the
MMF group the platelet count values were already numerically
higher than in vehicle mice at eight months, but a statistical
significance was not reached.
Effect of MMF on body weights
As shown in Table 3 NZBxW mice given MMF gained weight in
a similar manner to mice given vehicle during the entire study.
This documents a general tolerability of MMF in NZBxW mice
and would exclude a major gastrointestinal toxicity of the drug.
Effect of MMF on lupus mice survival
Figure 3 shows the survival curves of vehicle and MMF-treated
NZBxW mice. In group given the vehicle 50% of mice were alive
at 9.5 months of age, with 100% of mortality being reached at 15
months of age. By contrast, treatment with MMF significantly
(P < 0.02) prolonged life survival of NZBxW mice in respect to
vehicle. Thus, at 9.5 months of age 80% of MMF-treated mice still
survived. Due to the efficacy of treatment 100% of mortality was
observed eight months later than in the vehicle group, that is, at
23 months of age.
An autopsy was systematically performed on animals that were
sacrificed because of severe clinical illness, or in animals found
dead in their cages where autolysis had not progressed too far for
an adequate histological diagnosis to be made. In none of the
MMF-treated mice could tumor formation or signs of infection be
detected that was at variance to what has been described previ-
ously for lupus mice treated with immunosuppressant agents like
cyclophosphamide [13, 26].
Renal histology
Morphological analysis was performed on renal biopsies taken
from terminally ill NZBxW mice. As expected, in both groups of
animals glomerular changes were pronounced with endocapillary
hypercellularity (mean score: vehicle 1.7; MMF 1.5) associated
with a focal extracapillary proliferation (mean score 1.2 for both
groups). Immune complexes were detected in the mesangium and
on subendothelial aspect of giomerular basement membrane.
Interstitial inflammation, fibrosis and tubular damage were severe
(mean score: vehicle 2.2; MMF 1.7).
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Fig. 3. Survival rate in NZBxW mice given vehicle or MMF from three
months of age. At six months of age all animals from both groups were
alive. MMF significantly (P < 0.02) prolonged life survival in respect to
vehicle.
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Table 4. Effects of the most-used treatment modalities on survival in NZBxW mice
Treatment Dose
Start of treatment Observation time .Survival
% Referencesmonths of age
CyP 1.8 mg/mouse/wk i.p. 4—6.5 12 90 (vs. control 0) [13, 37]
CyP 25 mg/kg/wk i.p. 9—11 14—16 40 (vs. control 0) [261
CyP 1.5 mg/kg/day 5 12 40 [381
AZAT 1.5 mg/kg/day 5 12 40 [38]
MPS 1.5 mg/kg/day 5 12 40 [38]
CyP+AZAT+MPS 1.5 mg/kg/day (each drug) 5 12 90 (vs. control 5) [38]
AZAT 5 mg/kg/day p.o. 2.5 16 29 [39]
MPS 5 mg/kg/day p.o. 2.5 16 50 [39]
AZAT+MPS 5 mg/kg/day p.o. (each drug) 2.5 16 93 (vs. control 20) [39]
CsA 100 mg/kg/wk p.o. 2 12 70 (vs. control 40) [40]
FK 506 2.5 mg/kg 3xwk i.p. 3 11 75 (vs. control 10) [41]
MMF 60 mg/kg/day p.o. 3 12 65 (vs. control 20) present study
Abbreviations are: CyP, cyclophosphamide; MPS, methylprednisolone; AZAT, azathioprine; CsA, cyclosporine; MMF, mycophenolate mofetil.
Therapeutic effect of MMF on lupus mice survival
MMF treatment when started at five months of age had a
favorable effect on survival of NZBxW mice. Actually, survival in
group given the vehicle was 50% at nine months of age, when 90%
of the MMF-treated mice were still alive. These findings were
consistent with those observed in the prevention study.
Discussion
In the present study, we documented that MMF given as the
sole immunosuppressant limits systemic signs of the disease and
retards the expression of renal symptoms in NZBxW mice. MMF
also ameliorates the evolution of renal disease and even more
importantly prolongs life as compared to untreated animals.
Specifically, MMF prevented leukopenia and anemia, retarded
the development of> 3 mg/day proteinuria to a significant extent,
and protected from renal function deterioration. The drug was
extremely well tolerated, with no detectable toxicity nor enhanced
incidence of malignancies.
Glucocorticoids and cytotoxics, which are widely used for the
treatment of human SLE, provide a substantial control of the
disease with a clear improvement of long-term prognosis reported
in the last 30 years; however, these drugs have several serious side
effects. Patients given high-dose prednisone suffer from devastat-
ing steroid-related morbidity, which includes hypertension, infec-
tion, accelerated atherosclerosis, obesity, diabetes, aseptic bone
necrosis [27]. Even if steroid-related side-effects in the long-term
are less frequent and less severe with methylprednisolone pulse
therapy and low-dose maintenance prednisone, hyperglycemia
and hypercoagulation cannot be avoided [28]. Data from a
prospective randomized trial by NIH involving 111 patients
assigned to receive prednisone alone or cytotoxic drugs, such as
azathioprine and/or cyclophosphamide, plus moderate doses of
prednisone showed that those given cytotoxic therapy had less
deterioration of renal function and were less likely to die from
renal failure than patients given steroid alone [29]. However,
patients treated wth cytotoxic agents showed progressive bone
marrow depression, gonadal toxicity and hemorrhagic cystitis, and
enhanced incidence of opportunistic infections and cancer. In the
last 30 years different treatment modalities have been tested in
experimental lupus nephritis (Table 4). An early study by Russell
and Hicks [13] described that cyclophosphamide treatment pro-
longed the mouse lifespan, yet they also reported that these mice
had a high rate of infections, and some 30% of animals died with
evidence of malignancies mostly of non-lymphoid origin, which
included hepatomas, ovarian tumors, spindle-cell sarcomas in the
salivary-gland regions and pulmonary adenoma. Accordingly,
twenty years later Waer et al [26] showed that pulse cyclophos-
phamide therapy effectively retarded renal disease and prolonged
survival to a similar extent as total lymphoid irradiation, but found
that it was accompanied by an excess mortality mainly due to
lymphomas and viral infection. There are also studies that cyclo-
sporine and FK 506 reduce renal damage in lupus mice [30, 31].
However, the nephrotoxicity of the above molecules would con-
siderably limit their clinical application at least in patients with the
most severe nephritis, who with these drugs can develop irrevers-
ible renal dysfunction. Our present finding that MMF retards the
development of renal disease in lupus-prone NZBxW mice sug-
gests that MMF can now be regarded as an attractive and less
toxic alternative to the above molecules. The effect of MMF is
possibly the result of its antiproliferative properties on T- and
B-lymphocytes and of its capacity of inhibiting the formation of
autoantibodies [15], as also documented by our present data of a
reduced production of anti-DNA antibodies in the MMF-treated
group as compared to the vehicle. Inhibiting the formation of
autoantibodies would reduce immune complexes in the circula-
tion and their consequent deposition in the kidney, the most likely
mechanism by which MMF retards the onset of proteinuria and
renal function impairment and prolongs life. An alternative
explanation for the effect of MMF of retarding the expression of
renal disease in lupus nephritis rests on the property of the
molecule to inhibit the glycosilation of proteins involved in
leukocyte adhesion and attachment to endothelial cells [15]. It has
been shown that, by depleting GTP, MMF inhibits the transfer of
mannose and fucose to glycoproteins that function as adhesion
molecules, which include P- and E-selectins, VCAM-1 and L-
selectin, and their specific counter receptors. This would limit the
adesion of leukocytes to endothelial cells and to target cells.
Consistent with this latter interpretation are data that treatment
of either T-cells or interleukin-1 activated endothelial cells with
MMF decreased leukocyte attachment to the endothelium [15].
That limiting of leukocyte attachment to the endothelium can
indeed explain the effect of MMF of retarding renal disease
expression in experimental lupus rests on data that soluble
interferon-gamma receptor [32], anti-interleukin 10 antibodies
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[33] or anti-CD4 monoclonal antibodies [34], all of which reduce
the rate of recruitment of inflammatory cells into the kidney, also
considerably limit renal damage in experimental lupus. On the
other hand, there is increasing evidence that infiltrates of mono-
cytes within the glomeruli in lupus, as in other forms of glomer-
ulonephritis, precede the development of glomerular structural
lesions [351 andcan be limited by mononuclear cell depletion [361.
In conclusion, we have documented that MMF treatment
ameliorates systemic and renal manifestations of the disease in
experimental lupus nephritis and prolongs animal survival. These
results imply that clinical studies should be planned to explore the
exciting possibility that MMF, by virtue of its selective immuno-
suppressive properties on B- and T-cells, can be employed in
human lupus as a steroid sparing drug or as a possible alternative
to cytotoxics, considering that it is well tolerated in renal trans-
plant patients and that, despite its gastrointestinal toxicity, its
overall safety profile appears superior to azathioprine.
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